Approvals by the China NMPA in 2025.
Nature reviews. Drug discovery • Vol. 25, Issue 3 • 2026
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.
Signal transduction and targeted therapy • Vol. 10, Issue 1 • 2025
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Bioorganic & medicinal chemistry letters • Vol. 107 • 2024
The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models.
Breast cancer (Dove Medical Press) • Vol. 15 • 2023